Diagnostic and therapeutic value of progastrin‐releasing peptide on small‐cell lung cancer: A Single‐Center Experience in China |
| |
| Authors: | Xiao‐Yuan Wu Yang‐Bo Hu Hui‐Juan Li Bing Wan Chen‐Xi Zhang Bin Zhang Huan Hu Qun Zhang Tang‐Feng Lv Ping Zhan Yong Song |
| |
| Affiliation: | 1. Central Laboratory, Nanjing Chest Hospital, School of Medicine, Southeast University, Nanjing, China;2. Department of Respiratory Medicine, Jinling Hospital, Medical School of Southeast University, Nanjing, China;3. Department of Respiratory Medicine, Jinling Hospital, Nanjing University Institute of Respiratory Medicine, Nanjing University School of Medicine, Nanjing, China;4. Department of Respiratory and Critical Medicine, Nanjing Jiangning Hospital, The Affiliated Hospital of Nanjing Medical University, Nanjing, China;5. Department of ICU, The Affiliated Hospital of Jiangsu University, Zhenjiang, China;6. Department of Respiratory Medicine and Central Laboratory, Nanjing Chest Hospital, School of Medicine, Southeast University, Nanjing, China |
| |
| Abstract: | We aimed to compare the diagnostic efficiency of proGRP and NSE on SCLC and to investigate whether the change of proGRP level would predict therapeutic response. Patients who were firstly diagnosed pathologically in Nanjing Chest Hospital and measured proGRP level consecutively were enrolled in the study. ProGRP level was detected using Elecsys ProGRP Assay. Totally 75 SCLC, 234 NSCLC and 264 benign lung diseases (BLD) were enrolled. Both proGRP and NSE levels in SCLC were significantly higher than those in NSCLC and BLD, and proGRP in extensive stage SCLC was higher than which in limited stage (P ≤ .001). The diagnostic efficiency of proGRP on SCLC was higher than that of NSE, but when the two biomarkers were bind together, the diagnostic efficiency was the best. When SCLC was differentiated from NSCLC and BLD, the cut‐off values were 114.35 pg/mL and 162.55 pg/mL respectively. For treatment responsive patients, proGRP level decreased markedly after the first cycle of therapy and kept a continued momentum of decline during treatment. But for unresponsive patients, no obvious decline was observed. ProGRP had higher diagnostic efficiency on SCLC when compared to NSE, and it could better predict therapeutic response of pulmonary target lesions on chemotherapy. |
| |
| Keywords: | diagnosis neuron‐specific enolase progastrin‐releasing peptide small‐cell lung cancer therapeutic monitoring |
|
|
